AIM's logo.
Ticker Symbol: AIM

AIM ImmunoTech Inc

$1.64 - 15-07-2024 4 p.m. ET

Exchange: NYSE MKT LLC Country: US Currency: USD Asset Type: Common Stock CIK:0000946644

Company Profile

aim immunotech inc., an immuno-pharma company, focuses on the research and development of therapeutics to treat multiple types of cancers and immune-deficiency disorders in the united states. the company's products include alferon n injection, an injectable formulation of natural alpha interferon to treat a category of genital warts, a sexually transmitted disease; and ampligen, a drug of macromolecular ribonucleic acid molecule for the treatment of chronic fatigue syndrome. it is also developing ampligen for the treatment of hepatitis b and hiv, as well as patients with renal cell carcinoma, malignant melanoma, non-small cell lung, ovarian, breast, colorectal, urothelial, prostate, and pancreatic cancer. aim immunotech inc. has research agreement with the japanese national institute of infectious diseases and shionogi & co., ltd. to test its drug ampligen as an adjuvant therapy for covid-19, the new coronavirus infectious disease caused by sars-cov-2. the company was formerly known as

Sector: Manufacturing
Industry: Biological Product (except Diagnostic) Manufacturing
Standard Industrial Classification Code (SIC code): 2836
Address: 2117 SW Highway 484
CEO: Thomas Equels
  • Health Technology
  • Biotechnology
  • Manufacturing
  • Biological Product (except Diagnostic) Manufacturing


Last Updated: October 20, 2023 03:00 PM EST
Previous Close: $0.45
Change: -$0.01 ( -4.17%)
Days Range: $0.45 - $0.47
Beta: 0.84
52wk. High: $0.83
52wk. Low: $0.29
Ytd. Change 40.84%
50 Day Moving Average: $0.52
200 Day Moving Average: $0.54
Shares Outstanding: 48670427


Market Cap: 2.2B
PE Ratio: -1.13
EPS (TTM): -0.401


Dividend Per Share (TTM): -
Dividend Yield (TTM): 0.00%
Ex-Dividend Date: N/A